Table 2.
Treatments with specific arabinoxylan-degrading enzymes and relevant inclusion levels in animal triala
| Treatments | CTL | EX | EXA | EXF | XAF-1 | XAF-2 | XAF-3 | XAF-4 |
|---|---|---|---|---|---|---|---|---|
| EX | 0 |
54 (600) |
54 (600) |
54 (600) |
54 (600) |
63 (700) |
63 (700) |
54 (600) |
| EA | 0 | 0 |
5 (500) |
0 |
5 (500) |
6 (600) |
4 (400) |
6.7 (668) |
| EF | 0 | 0 | 0 |
0.4 (400) |
0.4 (400) |
0.5 (500) |
0.5 (500) |
0.4 (400) |
aTreatments: CTL, basal diet (control); EX, basal diet supplemented with core xylanase; EXA, basal diet supplemented with xylanase accompanied by EA; EXF, basal diet supplemented with xylanase accompanied by EF; XAF-i (i = 1–4), compound groups with the above three enzymes. The same as below, also involving all figures. Bold values in parentheses are additive dosages (mg/kg) in this animal experiment, while the values outside brackets are the appropriate inclusion levels (U/g) obtained from the in vitro screening process